utaa09
Cell therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2023 (NCT06092047)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06503211 | Phase 1 | Jul 31, 2024 | Nanjing Medical University |
| NCT06092047 | Early Phase 1 (Phase 1) | Oct 31, 2023 | Anhui Medical University, Anhui Province Cancer Hospital, PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anhui Medical University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Anhui Province Cancer Hospital | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Nanjing Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | For profit | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1